Blood Cancer Journal

Article	Citations
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	1355
Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis	410
Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study	118
Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases	116
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	107
Large differencies in age-specific survival in multiple myeloma in the nordic countries	106
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries	104
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	101
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	98
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis	96
Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change	96
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19	87
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial	85
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study	85
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	83
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity a	81
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?	73
Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital	68
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation	68
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT	66
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia	65
Genomic landscape of hyperleukocytic acute myeloid leukemia	63
The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transp	62
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression	62
Disparities in time to treatment with oral antimyeloma medications	61

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies	61
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	56
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis	54
The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders	53
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy	53
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma	53
Time independent factors that predict relapse in adults with acute myeloid leukemia	53
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmac	52
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas	50
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy	50
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	47
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	47
Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents	45
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	45
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)	43
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	43
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma	42
Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients	41
Comprehensive Review of AL amyloidosis: some practical recommendations	41
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib	39
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach	38
Survival trends in hematological malignancies in the Nordic countries through 50 years	36
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	36
Sensitive multiple myeloma disease monitoring by mass spectrometry	36
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements	36
Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience	35
Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning	35
Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution	35
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence	35
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia	34
Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy	33
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia	33
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels	33
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation	33
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	32
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	32
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm	31
Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT	31
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma	31
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib	31
Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma	31
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies	30
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement	30
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party	29
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	29
B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation	29
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	29
Genetically determined telomere length and multiple myeloma risk and outcome	29
A clinical perspective on plasma cell leukemia; current status and future directions	28
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience	28

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity	28
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia	27
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	27
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia	27
Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index	26
Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis	26
Asciminib in chronic myeloid leukemia: many questions still remain to be answered	26
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse	26
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score	25
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib	25
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy	24
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation	24
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome	24
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	24
Clinical features and outcomes in primary nervous system histiocytic neoplasms	24
In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms	24
Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia	24
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen	23
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review	23
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML	23
MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma	22
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis	22
A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease	22
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)	22
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	22
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells	21
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	21
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors	21
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma	21
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms	21
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma	21
Global burden of hematologic malignancies and evolution patterns over the past 30 years	21
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in t	21
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia	20
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients	20
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins	20
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia	19
Cost comparison of post-remission strategies in younger and older AML patients in France	19
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients	19
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia	19
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms	19
A multiparametric niche-like drug screening platform in acute myeloid leukemia	19
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy	19
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome	19
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	18
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	18
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	18
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study	18
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms	17
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review	17
Molecular monitoring in CML—a modern example of an old proverb	17
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy	17
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	17
Update on the management of relapsed/refractory chronic lymphocytic leukemia	17
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab	17
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies	17
Author Correction: Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria	17
Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma	16
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia	16
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	16
Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation	16
Zanubrutinib: past, present, and future	16
Genetics and pathologic landscape of lineage switch of acute leukemia during therapy	16
Exercise-induced release of cardiac and skeletal muscle injury biomarkers in patients with chronic myeloid leukemia receiving TKI therapy	16
Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm	15
Early mortality after chemotherapy as a quality indicator—the leukemia perspective	15
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms	15
Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India	15
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study	15
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes	15
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-	15
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma	15
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020	15
Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients	15
Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma	15
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy	15
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma	15
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression	14
BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified	14
Drug importation: limitations of current proposals and opportunities for improvement	14

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial	14
Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early	14
Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy	14
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment	14
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study	14
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis	14
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	14
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	14
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis	14
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia	13
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies	13
MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study	13
Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study	13
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine	13
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway	13
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	13
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience	13
Racial disparities in patients diagnosed with light chain (AL) amyloidosis	12
Mutations and thrombosis in essential thrombocythemia	12
Management of patients with lower-risk myelodysplastic syndromes	12
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study	12
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases	12
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study	12
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation	12
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score	12
One thousand patients with essential thrombocythemia: the Mayo Clinic experience	12
Acute myeloid leukemia: current progress and future directions	12
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study	12
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma	12
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group	12
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma	11
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6	11
Racial disparities in multiple myeloma and access to stem cell transplantation	11
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival	11
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia	11
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations	11
Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma	11
Using Mendelian Randomisation to search for modifiable risk factors influencing the development of clonal haematopoiesis	11
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era	11
Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience	11
Queries regarding the two papers each reporting on 1000 essential thrombocythemia patients in BCJ	11
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	11
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”	11
First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018	11
Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series	11
Minor GPI(-) granulocyte populations in aplastic anemia and healthy individuals derived from a few PIGA-mutated hematopoietic stem progenitor cells	11
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	11
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL	11